User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4

Primary tabs

download
  • Open access
  • PDF
  • 153.21 K
Leung, Daniel H. Wirth, Stefan Yao, Betty B. Viani, Rolando M. Gonzalez-Peralta, Regino P. Sokal, Etienne [UCL] Rosenthal, Philip

In adults, treatment of hepatitis C virus (HCV) infection with ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with or without dasabuvir (DSV) and ±ribavirin (RBV) results in high rates of sustained virologic response (SVR). However, these regimens have not been investigated in adolescents. This ongoing, open-label, phase 2/3 study evaluated the pharmacokinetics, safety, and efficacy of OBV/PTV/r+DSV±RBV treatment for 12 weeks in adolescents infected with HCV genotype (GT) 1 without cirrhosis (part 1) and the safety and efficacy of OBV/PTV/r±DSV±RBV treatment for 12 or 24 weeks in adolescents infected with GT1 or GT4 without cirrhosis or with compensated cirrhosis (parts 1 and 2). Patients were 12-17 years of age and treatment naive or interferon experienced. Treatment regimens were based on HCV GT and cirrhosis status. Endpoints were SVR at posttreatment week 12 (SVR12), adverse events (AEs), and pharmacokinetic parameters. Thirty-eight adolescents were enrolled, 66% were female patients, and 76% were White; 42%, 40%, and 18% of patients had HCV GT1a, GT1b, and GT4 infections, respectively. Median age was 15 years (range, 12-17 years), and 1 patient had cirrhosis. The SVR12 rate was 100% (38/38; 95% confidence interval [CI], 90.8%-100%). No treatment-emergent grade 3 or 4 laboratory abnormalities were reported. No serious AEs occurred on treatment, and no AEs led to study drug discontinuation. The most common AEs were headache (21%), fatigue (18%), nasopharyngitis (13%), pruritus (13%), and upper respiratory tract infection (11%). Intensive pharmacokinetic results showed OBV, PTV, DSV, and ritonavir drug exposures were comparable to those seen in adults. Conclusion: Treatment with OBV/PTV/r±DSV±RBV was well tolerated and highly efficacious in adolescents with HCV GT1 or GT4 infection.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2018
Language Anglais
Journal information "Hepatology Communications" - Vol. 2, no.11, p. 1311-1319 (2018)
Publisher Wiley
issn 2471-254X
Publication status Publié
Affiliations UCL - SSS/IREC/PEDI - Pôle de Pédiatrie
UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique
Links
  1. AASLD-IDSA https://www.hcvguidelines.org
  2. Pawlotsky Jean-Michel, Negro Francesco, Aghemo Alessio, Berenguer Marina, Dalgard Olav, Dusheiko Geoffrey, Marra Fiona, Puoti Massimo, Wedemeyer Heiner, EASL Recommendations on Treatment of Hepatitis C 2018, 10.1016/j.jhep.2018.03.026
  3. Blach Sarah, Zeuzem Stefan, Manns Michael, Altraif Ibrahim, Duberg Ann-Sofi, Muljono David H, Waked Imam, Alavian Seyed M, Lee Mei-Hsuan, Negro Francesco, Abaalkhail Faisal, Abdou Ahmed, Abdulla Maheeba, Rached Antoine Abou, Aho Inka, Akarca Ulus, Al Ghazzawi Imad, Al Kaabi Saad, Al Lawati Faryal, Al Namaani Khalid, Al Serkal Youssif, Al-Busafi Said A, Al-Dabal Layla, Aleman Soo, Alghamdi Abdullah S, Aljumah Abdulrahman A, Al-Romaihi Hamad E, Andersson Monique I, Arendt Vic, Arkkila Perttu, Assiri Abdullah M, Baatarkhuu Oidov, Bane Abate, Ben-Ari Ziv, Bergin Colm, Bessone Fernando, Bihl Florian, Bizri Abdul R, Blachier Martin, Blasco Antonio J, Mello Carlos E Brandão, Bruggmann Philip, Brunton Cheryl R, Calinas Filipe, Chan Henry L Y, Chaudhry Asad, Cheinquer Hugo, Chen Chien-Jen, Chien Rong-Nan, Choi Moon Seok, Christensen Peer B, Chuang Wan-Long, Chulanov Vladimir, Cisneros Laura, Clausen Mette R, Cramp Matthew E, Craxi Antonio, Croes Esther A, Dalgard Olav, Daruich Jorge R, de Ledinghen Victor, Dore Gregory J, El-Sayed Manal H, Ergör Gul, Esmat Gamal, Estes Chris, Falconer Karolin, Farag Elmoubashar, Ferraz Maria L G, Ferreira Paulo R, Flisiak Robert, Frankova Sona, Gamkrelidze Ivane, Gane Ed, García-Samaniego Javier, Khan Amir Ghafoor, Gountas Ilias, Goldis Adrian, Gottfredsson Magnús, Grebely Jason, Gschwantler Michael, Pessôa Mário Guimarães, Gunter Jessie, Hajarizadeh Behzad, Hajelssedig Omer, Hamid Saeed, Hamoudi Waseem, Hatzakis Angelos, Himatt Sayed M, Hofer Harald, Hrstic Irena, Hui Yee-Tak, Hunyady Bela, Idilman Ramazan, Jafri Wasim, Jahis Rohani, Janjua Naveed Z, Jarčuška Peter, Jeruma Agita, Jonasson Jón G, Kamel Yasser, Kao Jia-Horng, Kaymakoglu Sabahattin, Kershenobich David, Khamis Jawad, Kim Young S, Kondili Loreta, Koutoubi Zaher, Krajden Mel, Krarup Henrik, Lai Moon-sing, Laleman Wim, Lao Wai-cheung, Lavanchy Daniel, Lázaro Pablo, Leleu Henri, Lesi Olufunmilayo, Lesmana Laurentius A, Li Michael, Liakina Valentina, Lim Young-Suk, Luksic Boris, Mahomed Adam, Maimets Matti, Makara Mihály, Malu Abraham O, Marinho Rui T, Marotta Paul, Mauss Stefan, Memon Muhammad S, Correa Maria C Mendes, Mendez-Sanchez Nahum, Merat Shahin, Metwally Ammal M, Mohamed Rosmawati, Moreno Christophe, Mourad Fadi H, Müllhaupt Beat, Murphy Kimberly, Nde Helen, Njouom Richard, Nonkovic Diana, Norris Suzanne, Obekpa Solomon, Oguche Stephen, Olafsson Sigurður, Oltman Marian, Omede Ogu, Omuemu Casimir, Opare-Sem Ohene, Øvrehus Anne L H, Owusu-Ofori Shirley, Oyunsuren Tsendsuren S, Papatheodoridis George, Pasini Ken, Peltekian Kevork M, Phillips Richard O, Pimenov Nikolay, Poustchi Hossein, Prabdial-Sing Nishi, Qureshi Huma, Ramji Alnoor, Razavi-Shearer Devin, Razavi-Shearer Kathryn, Redae Berhane, Reesink Henk W, Ridruejo Ezequiel, Robbins Sarah, Roberts Lewis R, Roberts Stuart K, Rosenberg William M, Roudot-Thoraval Françoise, Ryder Stephen D, Safadi Rifaat, Sagalova Olga, Salupere Riina, Sanai Faisal M, Avila Juan F Sanchez, Saraswat Vivek, Sarmento-Castro Rui, Sarrazin Christoph, Schmelzer Jonathan D, Schréter Ivan, Seguin-Devaux Carole, Shah Samir R, Sharara Ala I, Sharma Manik, Shevaldin Anatoly, Shiha Gamal E, Sievert William, Sonderup Mark, Souliotis Kyriakos, Speiciene Danute, Sperl Jan, Stärkel Peter, Stauber Rudolf E, Stedman Catherine, Struck Daniel, Su Tung-Hung, Sypsa Vana, Tan Soek-Siam, Tanaka Junko, Thompson Alexander J, Tolmane Ieva, Tomasiewicz Krzysztof, Valantinas Jonas, Van Damme Pierre, van der Meer Adriaan J, van Thiel Ingo, Van Vlierberghe Hans, Vince Adriana, Vogel Wolfgang, Wedemeyer Heiner, Weis Nina, Wong Vincent WS, Yaghi Cesar, Yosry Ayman, Yuen Man-fung, Yunihastuti Evy, Yusuf Aasim, Zuckerman Eli, Razavi Homie, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study, 10.1016/s2468-1253(16)30181-9
  4. WHO https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
  5. CDA Foundation https://cdafound.org/featured3/
  6. Delgado-Borrego Aymin, Smith Lesley, Jonas Maureen M., Hall Cyndena A., Negre Betania, Jordan Sergio H., Ogrodowicz Matthew, Raza Roshan, Ludwig David A., Miller Tracie, Lipshultz Steven E., Gonzalez-Peralta Regino, Chung Raymond T., Expected and Actual Case Ascertainment and Treatment Rates for Children Infected with Hepatitis C in Florida and the United States: Epidemiologic Evidence from Statewide and Nationwide Surveys, 10.1016/j.jpeds.2012.05.002
  7. Bortolotti Flavia, Verucchi Gabriella, Cammà Calogero, Cabibbo Giuseppe, Zancan Lucia, Indolfi Giuseppe, Giacchino Raffaella, Marcellini Matilde, Marazzi Maria Grazia, Barbera Cristiana, Maggiore Giuseppe, Vajro Pietro, Bartolacci Samuela, Balli Fiorella, Maccabruni Anna, Guido Maria, Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease, 10.1053/j.gastro.2008.02.082
  8. García-Monzón Carmelo, Jara Paloma, Fernández-Bermejo Miguel, Hierro Loreto, Frauca Esteban, Camarena Carmen, Díaz Carmen, De la Vega Angela, Larrauri Javier, García-Iglesias Consuelo, Borque María J., Sanz Paloma, García-Buey Luisa, Moreno-Monteagudo José A., Moreno-Otero Ricardo, Chronic hepatitis C in children: A clinical and immunohistochemical comparative study with adult patients : Chronic Hepatitis C in Children: A Clinical and Immunohistochemical Comparative Study With Adult Patients, 10.1002/hep.510280633
  9. Barshes Neal R., Udell Ian W., Lee Timothy C., O'Mahony Christine A., Karpen Saul J., Carter Beth A., Goss John A., The natural history of hepatitis C virus in pediatric liver transplant recipients, 10.1002/lt.20793
  10. Goodman Zachary D., Makhlouf Hala R., Liu Lea, Balistreri William, Gonzalez-Peralta Regino P., Haber Barbara, Jonas Maureen M., Mohan Parvathi, Molleston Jean P., Murray Karen F., Narkewicz Michael R., Rosenthal Philip, Smith Lesley J., Robuck Patricia R., Schwarz Kathleen B., Pathology of chronic hepatitis C in children: Liver biopsy findings in the Peds-C Trial, 10.1002/hep.22094
  11. Genentech https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf
  12. Ghany Marc G., Strader Doris B., Thomas David L., Seeff Leonard B., Diagnosis, management, and treatment of hepatitis C: An update, 10.1002/hep.22759
  13. Indolfi Giuseppe, Hierro Loreto, Dezsofi Antal, Jahnel Jörg, Debray Dominique, Hadzic Nedim, Czubkowski Piotr, Gupte Girish, Mozer-Glassberg Yael, van der Woerd Wendy, Smets Françoise, Verkade Henkjan J., Fischler Björn, Treatment of Chronic Hepatitis C Virus Infection in Children : A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition, 10.1097/mpg.0000000000001872
  14. AbbVie Inc https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206619s017lbl.pdf
  15. AbbVie Inc. https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf
  16. AbbVie Inc. https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf
  17. AbbVie Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207931s011lbl.pdf
  18. Andreone, Gastroenterology, 147, e351 (2014)
  19. Feld Jordan J., Kowdley Kris V., Coakley Eoin, Sigal Samuel, Nelson David R., Crawford Darrell, Weiland Ola, Aguilar Humberto, Xiong Junyuan, Pilot-Matias Tami, DaSilva-Tillmann Barbara, Larsen Lois, Podsadecki Thomas, Bernstein Barry, Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin, 10.1056/nejmoa1315722
  20. Ferenci Peter, Bernstein David, Lalezari Jacob, Cohen Daniel, Luo Yan, Cooper Curtis, Tam Edward, Marinho Rui T., Tsai Naoky, Nyberg Anders, Box Terry D., Younes Ziad, Enayati Pedram, Green Sinikka, Baruch Yaacov, Bhandari Bal Raj, Caruntu Florin Alexandru, Sepe Thomas, Chulanov Vladimir, Janczewska Ewa, Rizzardini Giuliano, Gervain Judit, Planas Ramon, Moreno Christophe, Hassanein Tarek, Xie Wangang, King Martin, Podsadecki Thomas, Reddy K. Rajender, ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV, 10.1056/nejmoa1402338
  21. Hézode Christophe, Asselah Tarik, Reddy K Rajender, Hassanein Tarek, Berenguer Marina, Fleischer-Stepniewska Katarzyna, Marcellin Patrick, Hall Coleen, Schnell Gretja, Pilot-Matias Tami, Mobashery Niloufar, Redman Rebecca, Vilchez Regis A, Pol Stanislas, Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial, 10.1016/s0140-6736(15)60159-3
  22. Poordad Fred, Hezode Christophe, Trinh Roger, Kowdley Kris V., Zeuzem Stefan, Agarwal Kosh, Shiffman Mitchell L., Wedemeyer Heiner, Berg Thomas, Yoshida Eric M., Forns Xavier, Lovell Sandra S., Da Silva-Tillmann Barbara, Collins Christine A., Campbell Andrew L., Podsadecki Thomas, Bernstein Barry, ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis, 10.1056/nejmoa1402869
  23. Zeuzem Stefan, Jacobson Ira M., Baykal Tolga, Marinho Rui T., Poordad Fred, Bourlière Marc, Sulkowski Mark S., Wedemeyer Heiner, Tam Edward, Desmond Paul, Jensen Donald M., Di Bisceglie Adrian M., Varunok Peter, Hassanein Tarek, Xiong Junyuan, Pilot-Matias Tami, DaSilva-Tillmann Barbara, Larsen Lois, Podsadecki Thomas, Bernstein Barry, Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin, 10.1056/nejmoa1401561
  24. Ganne-Carrié Nathalie, Ziol Marianne, de Ledinghen Victor, Douvin Catherine, Marcellin Patrick, Castera Laurent, Dhumeaux Daniel, Trinchet Jean-Claude, Beaugrand Michel, Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases, 10.1002/hep.21420
  25. Druyts Eric, Thorlund Kristian, Wu Ping, Kanters Steve, Yaya Sanni, Cooper Curtis L., Mills Edward J., Efficacy and Safety of Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysis, 10.1093/cid/cis1031
  26. Balistreri William F., Murray Karen F., Rosenthal Philip, Bansal Sanjay, Lin Chuan-Hao, Kersey Kathryn, Massetto Benedetta, Zhu Yanni, Kanwar Bittoo, German Polina, Svarovskaia Evguenia, Brainard Diana M., Wen Jessica, Gonzalez-Peralta Regino P., Jonas Maureen M., Schwarz Kathleen, The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection : Balistreri et al., 10.1002/hep.28995
  27. Wirth Stefan, Rosenthal Philip, Gonzalez-Peralta Regino P., Jonas Maureen M., Balistreri William F., Lin Chuan-Hao, Hardikar Winita, Kersey Kathryn, Massetto Benedetta, Kanwar Bittoo, Brainard Diana M., Shao Jiang, Svarovskaia Evguenia, Kirby Brian, Arnon Ronen, Murray Karen F., Schwarz Kathleen B., Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection, 10.1002/hep.29278
  28. Yakoot Mostafa, El-Shabrawi Mortada H., AbdElgawad Manal M., Mahfouz Aml A., Helmy Sherine, Abdo Alaa M., El-Khayat Hisham R., Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection : , 10.1097/mpg.0000000000001968
  29. Lalezari Jacob, Sullivan J. Greg, Varunok Peter, Galen Edward, Kowdley Kris V., Rustgi Vinod, Aguilar Humberto, Felizarta Franco, McGovern Barbara, King Martin, Polepally Akshanth R., Cohen Daniel E., Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine, 10.1016/j.jhep.2015.03.029
Bibliographic reference Leung, Daniel H. ; Wirth, Stefan ; Yao, Betty B. ; Viani, Rolando M. ; Gonzalez-Peralta, Regino P. ; et. al. Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4. In: Hepatology Communications, Vol. 2, no.11, p. 1311-1319 (2018)
Permanent URL http://hdl.handle.net/2078.1/207484